COVID-19 fatality prediction in people with diabetes and prediabetes using a simple score upon hospital admission.


Journal

Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645

Informations de publication

Date de publication:
02 2021
Historique:
received: 05 10 2020
revised: 02 11 2020
accepted: 11 11 2020
pubmed: 18 11 2020
medline: 16 1 2021
entrez: 17 11 2020
Statut: ppublish

Résumé

To assess predictors of in-hospital mortality in people with prediabetes and diabetes hospitalized for COVID-19 infection and to develop a risk score for identifying those at the greatest risk of a fatal outcome. A combined prospective and retrospective, multicentre, cohort study was conducted at 10 sites in Austria in 247 people with diabetes or newly diagnosed prediabetes who were hospitalized with COVID-19. The primary outcome was in-hospital mortality and the predictor variables upon admission included clinical data, co-morbidities of diabetes or laboratory data. Logistic regression analyses were performed to identify significant predictors and to develop a risk score for in-hospital mortality. The mean age of people hospitalized (n = 238) for COVID-19 was 71.1 ± 12.9 years, 63.6% were males, 75.6% had type 2 diabetes, 4.6% had type 1 diabetes and 19.8% had prediabetes. The mean duration of hospital stay was 18 ± 16 days, 23.9% required ventilation therapy and 24.4% died in the hospital. The mortality rate in people with diabetes was numerically higher (26.7%) compared with those with prediabetes (14.9%) but without statistical significance (P = .128). A score including age, arterial occlusive disease, C-reactive protein, estimated glomerular filtration rate and aspartate aminotransferase levels at admission predicted in-hospital mortality with a C-statistic of 0.889 (95% CI: 0.837-0.941) and calibration of 1.000 (P = .909). The in-hospital mortality for COVID-19 was high in people with diabetes but not significantly different to the risk in people with prediabetes. A risk score using five routinely available patient variables showed excellent predictive performance for assessing in-hospital mortality.

Identifiants

pubmed: 33200501
doi: 10.1111/dom.14256
pmc: PMC7753560
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

589-598

Subventions

Organisme : This study was supported by unrestricted research grants to the Austrian Diabetes Association from NovoNordisk, Novartis, Sanofi, AstraZeneca and Boehringer Ingelheim.
Pays : International

Informations de copyright

© 2020 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

Références

Lancet Diabetes Endocrinol. 2016 Feb;4(2):148-58
pubmed: 26656292
Crit Care. 2020 Jul 9;24(1):406
pubmed: 32646467
Int J Surg. 2020 Nov;83:1-2
pubmed: 32927136
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Diabetes Care. 2020 Jul;43(7):1399-1407
pubmed: 32409498
Int J Surg. 2020 Jul;79:143-153
pubmed: 32422384
Diabetes Obes Metab. 2021 Feb;23(2):589-598
pubmed: 33200501
Diabetologia. 2020 Aug;63(8):1440-1452
pubmed: 32405783
Lancet Diabetes Endocrinol. 2020 Oct;8(10):813-822
pubmed: 32798472
Diabetologia. 2020 Aug;63(8):1500-1515
pubmed: 32472191
N Engl J Med. 1999 Dec 16;341(25):1906-12
pubmed: 10601511
Wien Klin Wochenschr. 2019 May;131(Suppl 1):6-15
pubmed: 30980151
Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-833
pubmed: 32798471
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Diabetes Care. 2020 Oct;43(10):2345-2348
pubmed: 32788285
Diabetes Care. 2020 Jul;43(7):1382-1391
pubmed: 32409504
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076

Auteurs

Harald Sourij (H)

Clinical Division for Endocrinology and Diabetology, Medical University Graz, Graz, Austria.
Center for Biomarker Research in Medicine (CBMed), Graz, Austria.

Faisal Aziz (F)

Clinical Division for Endocrinology and Diabetology, Medical University Graz, Graz, Austria.
Center for Biomarker Research in Medicine (CBMed), Graz, Austria.

Alexander Bräuer (A)

Medical Division for Endocrinology, Rheumatology and Acute Geriatrics, Wilhelminen Hospital Vienna, Vienna, Austria.

Christian Ciardi (C)

Clinical Division for Internal Medicine, Endocrinology, Diabetology and Metabolic Diseases, St. Vinzenz Hospital Zams, Zams, Austria.

Martin Clodi (M)

Clinical Division for Internal Medicine, Konventhospital Barmherzige Brüder Linz, Linz, Austria.

Peter Fasching (P)

Medical Division for Endocrinology, Rheumatology and Acute Geriatrics, Wilhelminen Hospital Vienna, Vienna, Austria.

Mario Karolyi (M)

4th Medical Division with Infectiology, SMZ Süd - KFJ-Hospital Vienna, Vienna, Austria.

Alexandra Kautzky-Willer (A)

Clinical Division for Endocrinology and Diabetology and Metabolic Diseases, AKH Vienna, Vienna, Austria.

Carmen Klammer (C)

Clinical Division for Internal Medicine, Konventhospital Barmherzige Brüder Linz, Linz, Austria.

Oliver Malle (O)

Clinical Division for Endocrinology and Diabetology, Medical University Graz, Graz, Austria.

Abderrahim Oulhaj (A)

Institute of Public Health, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.

Erich Pawelka (E)

4th Medical Division with Infectiology, SMZ Süd - KFJ-Hospital Vienna, Vienna, Austria.

Slobodan Peric (S)

3rd Department and Karl Landsteiner Institute for Metabolic Diseases and Nephrology, Clinic Hietzing, Vienna Health Care Group, Vienna, Austria.

Claudia Ress (C)

Department for Internal Medicine I, Medical University Innsbruck, Innsbruck, Austria.

Caren Sourij (C)

Clinical Division for Cardiology, Medical University Graz, Graz, Austria.

Lars Stechemesser (L)

Department for Internal Medicine I, Paracelsus Medical University, Salzburg, Austria.

Harald Stingl (H)

Clinical Division for Internal Medicine, Hospital Melk, Melk, Austria.

Thomas Stulnig (T)

3rd Department and Karl Landsteiner Institute for Metabolic Diseases and Nephrology, Clinic Hietzing, Vienna Health Care Group, Vienna, Austria.

Norbert Tripolt (N)

Clinical Division for Endocrinology and Diabetology, Medical University Graz, Graz, Austria.

Michael Wagner (M)

Clinical Division for Internal Medicine, Hospital Melk, Melk, Austria.

Peter Wolf (P)

Clinical Division for Endocrinology and Diabetology and Metabolic Diseases, AKH Vienna, Vienna, Austria.

Andreas Zitterl (A)

3rd Department and Karl Landsteiner Institute for Metabolic Diseases and Nephrology, Clinic Hietzing, Vienna Health Care Group, Vienna, Austria.

Susanne Kaser (S)

Department for Internal Medicine I, Medical University Innsbruck, Innsbruck, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH